Daily Bio News Summary — 2026-08-14: BMS's Zenbexus myeloma nod, Ovid's $294M epilepsy NewCo, and MapLight's schizophrenia bet

Today’s Harvest: 34 articles across 9 sources

Today’s batch of 34 biopharma news articles (after 30-day freshness, paywall, political/opinion, and URL-dedupe filters) spans therapeutics development (12), clinical regulatory (11), business & strategy (9), and careers & market (2). Source mix: PR Newswire FDA (8), Fierce Pharma (8), Fierce Biotech (4), Endpoints News (4), BioSpace (4), STAT News (3), MedCity News (2), FDA Newsroom (1). The day’s two structural stories are Bristol Myers Squibb’s first CELMoD franchise approval (Zenbexus for relapsed/refractory multiple myeloma — covered by Fierce Pharma, Endpoints News, and BioSpace) and the Ovid/Takeda soticlestat NewCo spin-out (Endpoints News).

Headline: BMS’s First CELMoD Approval (Zenbexus)

Bristol Myers Squibb secured its first FDA approval for the CELMoD franchise with Zenbexus (iberdomide) for relapsed/refractory multiple myeloma at $29,500/cycle, used in combination with Darzalex. Three outlets covered it (Fierce Pharma, Endpoints News, BioSpace) — this is the first-in-class approval for a Cereblon E3 Ligase Modulator in the post-Revlimid myeloma space, and BMS is positioning Zenbexus against generic Pomalyst and Revlimid erosion. (Fierce Pharma, Endpoints News, BioSpace, 2026-08-14)

Ovid/Takeda Soticlestat → Perceptive-Backed NewCo

Ovid Therapeutics and Takeda’s failed epilepsy drug soticlestat is getting new life as Perceptive Advisors launches a NewCo around it with up to $294M in funding. This is a classic “failed-but-not-dead” resurrection — soticlestat missed in Dravet and Lennox-Gastaut but has residual value, and Perceptive is the right sponsor to keep it alive at lower burn. (Endpoints News, 2026-08-14)

MapLight Goes All-In on ML-007C-MA

MapLight Therapeutics is shutting down its preclinical programs to focus all resources on ML-007C-MA, its Phase 3-ready schizophrenia asset, despite mixed Phase 2 results last month. Two outlets covered the pivot (Fierce Biotech, Endpoints News) — the strategic read is that MapLight believes the asset’s commercial ceiling justifies burning the discovery platform. (Fierce Biotech, Endpoints News, 2026-08-14)

Capricor Resubmits After Adcomm Setback

Capricor Therapeutics secured FDA agreement to file an amendment to its DMD application following last month’s bruising advisory committee meeting. The news sent shares soaring. This is the derisked-resubmit path after a CRL-style setback. (Fierce Biotech, 2026-08-14)

BioCryst CEO Strategy Reset

BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts — a positioning move to reassure investors that the external-discovery pivot is not a science retreat. (Fierce Biotech, 2026-08-14)

K2 Therapeutics Picks Up Former Legend CEO

K2 Therapeutics, founded in 2024 with a $50M MPM BioImpact seed round, has hired the recently-departed Legend Biotech CEO Wang to lead the cell-therapy startup. The Fierce Biotech Chutes & Ladders column carries the move. (Fierce Biotech, 2026-08-14)

Bicara Leadership Transition

Bicara Therapeutics president and COO Ryan Cohlhepp will take over as CEO; the company is also bringing J&J’s John Reed onto Madrigal’s board in a separate leadership note. (Endpoints News, 2026-08-14)

Phanes + ArkBio FDA Regulatory Wins

Two clinical-regulatory items from PR Newswire: (1) Phanes Therapeutics received FDA Fast Track Designation for spevatamig in advanced and metastatic biliary tract carcinoma; (2) ArkBio’s RSV antiviral ziresovir received FDA approval for Phase II clinical trial. Both are early-stage validation events. (PR Newswire, 2026-08-14)

FDA Issues EUA for New World Screwworm Drug

The FDA issued an Emergency Use Authorization for Simparica TRIO (sarolaner, moxidectin, pyrantel) for treatment of New World Screwworm in dogs and puppies — a rare animal-health EUA. (FDA Newsroom, 2026-08-13)

PTC Therapeutics Double-Down on Rare Disease

Two PTC Therapeutics items: (1) PTC is paying $211M to acquire the BLA-stage ST-920 Fabry disease program (medcity-auction winner); (2) PTC is acquiring ST-920 directly (PR Newswire). Both are parts of PTC’s Fabry disease strategic entry, the same week. (PR Newswire, MedCity News, 2026-08-12 → 2026-08-14)

Scholar Rock Novo Nordisk Plant Issue

Scholar Rock is rejigging its approval filing after the FDA classified the Novo Nordisk fill-finish plant as Official Action Indicated (OAI) for violations — a CMC-related filing delay. (BioSpace, 2026-08-11)

Vesalio + Aidoc + Perimeter: Med-Tech Regulatory Wins

Three medtech regulatory items: (1) Vesalio received FDA 510(k) clearance for pVasc NET, a next-gen peripheral mechanical thrombectomy device with integrated distal filter; (2) Aidoc’s CARE Body CT Multi-Triage received Medicare New Technology Add-on Payment eligibility; (3) Perimeter Medical Imaging’s Claire OCT system is being deployed at Intermountain Health in a landmark breast-cancer-surgery AI deployment. (PR Newswire, 2026-08-13 → 2026-08-14)

Karyopharm One-Month Salvage Window

Karyopharm Therapeutics has roughly a month left to salvage its cancer expansion plans — its reserves are depleted, a debt payment is due in four weeks, and cash runway extends only into next month. This is a default-watch situation for the XPO1 inhibitor franchise. (Fierce Pharma, 2026-08-13)

AstraZeneca Baxfendy Fails ICER Cost-Effectiveness Bar

AstraZeneca’s newly-approved first-in-class hypertension drug Baxfendy does not clear ICER’s bar for cost-effectiveness relative to its price. This is the first signal that ICER will push back on the launch pricing. (Fierce Pharma, 2026-08-13)

Neurocrine Vykat XR Safety Warnings

Neurocrine’s Prader-Willi drug Vykat XR is facing safety questions from clinicians — a group of PWS specialists has raised potential safety flags roughly 18 months after approval. This is a label-impact regulatory story. (Fierce Pharma, 2026-08-13)

Leo Pharma GPP Awareness Day

Two Leo Pharma items: (1) the company is gearing up for GPP (generalized pustular psoriasis) Awareness Day; (2) the company is launching a rare-disease education push for the 2nd annual GPP Awareness Day on August 13. (Fierce Pharma, 2026-08-13)

Epicrispr + Infinimmune $165M VC Round

Epicrispr Biotechnologies (epigenetic editing for FSHD muscular dystrophy) and Infinimmune snagged a combined $165M in VC cash. Two early-stage discovery-platform bets with limited clinical data so far. (BioSpace, 2026-08-11)

Boulevard Bio Launches (Deerfield, Schett, Nestle)

Deerfield Management has launched Boulevard Bio with scientific co-founders Georg Schett and Frank Nestle; the startup’s lead program is an autoimmune kidney-disorder drug that could compete with Vera Therapeutics’ approved asset and a Vertex Pharmaceuticals drug under FDA review. (MedCity News, 2026-08-01)

Aurisco + Salus: Manufacturing and Real-World Evidence

Two non-clinical items: (1) Aurisco Pharmaceutical is the first generic oligonucleotide manufacturer in the world successfully inspected by the US FDA; (2) Salus Scientific launched a Clinical Insights Series focused on real-world evidence in occupational radiation protection. (PR Newswire, 2026-08-12)

Fierce Pharma Asia: Legend Biotech’s First Profit

Legend Biotech became profitable for the first time as Carvykti (BCMA CAR-T) ramps; Taiho and Cullinan’s EGFR candidate delivered a phase 3 win (the zipalertinib readout); WuXi AppTec won a preliminary injunction against the Defense Department’s black-list designation. (Fierce Pharma, 2026-08-14)

STAT News: US/UK Healthcare Systems Analysis + Vaping/Cannabis Data

Two STAT health-systems items: (1) the US and UK health systems share a fatal flaw — both default to biomedical responses when social problems are the root cause; (2) young adults’ vaping and cannabis use hit all-time highs in 2025 according to a new survey. (STAT News, 2026-08-12 → 2026-08-14)

Fierce Pharma “A Genomics Library for the AI Era”

A Fierce Pharma “Top Line” interview with Andy Deubler on building a genomics library for the AI era — podcast/feature rather than hard news. (Fierce Pharma, 2026-08-14)

STAT Methadone Clinics Two-Years-Later

A STAT analysis two years after the methadone-clinic rules overhaul — are clinics really changing? Mixed picture in the piece. (STAT News, 2026-08-14)

What this batch is NOT telling us

• No major IPO filings or pricing today. The Boulevard Bio launch is a private raise, not an IPO.
• No AI-bio big-pharma partnership announcements. The Fierce Pharma “A genomics library for the AI era” is an interview, not a deal.
• No FDA approval actions beyond BMS Zenbexus (already widely reported) and the rare screwworm EUA. No PDUFA decisions, no CRLs in the headline.
• No Phase 3 readouts at scale beyond yesterday’s Taiho/Cullinan zipalertinib news (referenced again in the Fierce Pharma Asia wrap-up).
• No mega-cap M&A. The PTC Fabry disease moves are the biggest deals of the day, well below the $1B threshold for sector index impact.
• No PR Newswire items are FDA green-lights — all eight are Fast Track designations, 510(k) clearances, NTAP eligibility, or company announcements, not approval actions.

Reading order for limited-time readers

If you have 5 minutes, read in this order:

1. BMS Zenbexus approval (Fierce Pharma) — the day’s biggest regulatory action
2. Ovid/Takeda soticlestat NewCo (Endpoints News) — the day’s biggest strategic move
3. MapLight all-in on ML-007C-MA (Fierce Biotech) — the day’s most interesting pipeline prioritization
4. PTC’s Fabry disease play (MedCity News + PR Newswire) — the rare-disease trend continuing
5. Karyopharm one-month window (Fierce Pharma) — the day’s biggest default-watch story

How to read the underlying articles

Each markdown file in src/content/news/ has a sourceUrl field pointing to the original article; the sourceName field tags the publication. The companyId field (when present) points to the corresponding src/content/companies/<slug>.json profile. Today 13 new company profiles were created for first-time coverage of the relevant companies.

Today’s Articles (citation block)

1. STAT News, 2026-08-14 — U.S., U.K. health care systems share a fatal flaw
2. STAT News, 2026-08-14 — Two years after rules overhaul, have methadone clinics really changed?
3. PR Newswire, 2026-08-14 — Phanes Therapeutics Receives FDA Fast Track Designation for Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4. PR Newswire, 2026-08-14 — ArkBio’s RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
5. Fierce Pharma, 2026-08-14 — BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
6. Fierce Pharma, 2026-08-14 — A genomics library for the AI era
7. Fierce Pharma, 2026-08-14 — Fierce Pharma Asia — Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
8. Fierce Biotech, 2026-08-14 — Capricor soars on plan to amend DMD filing after adcomm setback
9. Fierce Biotech, 2026-08-14 — BioCryst CEO sets out strategy after ending internal discovery
10. Fierce Biotech, 2026-08-14 — Former Legend CEO lands at K2 — Chutes & Ladders
11. Fierce Biotech, 2026-08-14 — MapLight turns off preclinical tap to fund schizophrenia drug
12. Endpoints News, 2026-08-14 — FDA approves Bristol Myers’ multiple myeloma successor
13. Endpoints News, 2026-08-14 — Ovid and Takeda’s epilepsy drug gets new life at Perceptive-backed NewCo
14. Endpoints News, 2026-08-14 — Bicara shakes up leadership ahead of CEO departure; J&J’s John Reed joins Madrigal’s board
15. Endpoints News, 2026-08-14 — MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
16. BioSpace, 2026-08-14 — BMS welcomes new multiple myeloma drug as generics batter current portfolio
17. BioSpace, 2026-08-14 — Nascent US psychedelic therapy opportunity attracts overseas manufacturers
18. PR Newswire, 2026-08-14 — Aidoc’s CARE Body CT Multi-Triage receives eligibility for Medicare New Technology Add-on Payment
19. PR Newswire, 2026-08-14 — Intermountain Health Brings Perimeter’s Claire™ to the Operating Room, a Landmark in Breast Cancer Surgery Using AI
20. PR Newswire, 2026-08-14 — Vesalio Announces FDA 510(k) Clearance of pVasc NET, a Next-Generation Peripheral Mechanical Thrombectomy Device with Integrated Distal Filter
21. Fierce Pharma, 2026-08-13 — It’s crunch time for Karyopharm as company faces potential default next month
22. Fierce Pharma, 2026-08-13 — AZ’s blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
23. Fierce Pharma, 2026-08-13 — Neurocrine stands by blockbuster hopeful Vykat XR as Prader-Willi docs raise potential safety flags
24. Fierce Pharma, 2026-08-13 — Leo Pharma gears up for GPP awareness day
25. Fierce Pharma, 2026-08-13 — Leo Pharma readies rare disease education push for 2nd annual GPP awareness day
26. FDA Newsroom, 2026-08-13 — FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
27. STAT News, 2026-08-12 — Vaping and cannabis hit record highs among young adults in 2025: Survey
28. PR Newswire, 2026-08-12 — PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
29. PR Newswire, 2026-08-12 — Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
30. PR Newswire, 2026-08-12 — Salus Scientific Launches Clinical Insights Series to Advance Real-World Evidence in Occupational Radiation Protection
31. BioSpace, 2026-08-11 — Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
32. BioSpace, 2026-08-11 — Epicrispr, Infinimmune snag combined $165M in VC cash
33. MedCity News, 2026-08-01 — PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy
34. MedCity News, 2026-08-01 — Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder